Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...

The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease.

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced additions to its executive team and board of directors ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.